Therapeutic Strategies for Neuromyelitis Optica
Treatments for acute attacks of neuromyelitis optica (NMO) include steroid pulse therapy, plasma exchange, and intravenous immunoglobulin. Oral immunosuppressants, such as prednisolone and azathioprine, have also been used to prevent relapse. Recently, biologic agents such as eculizumab, satralizumab, inebilizumab, and rituximab have been approved for use in Japan. Although side effects caused by steroid therapy have been issues for patients in the past, active use of the newly approved biologics is expected to help patients avoid the adverse effects of steroids and improve their qualities of life.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:75 |
|---|---|
| Enthalten in: |
Brain and nerve = Shinkei kenkyu no shinpo - 75(2023), 5 vom: 17. Mai, Seite 493-497 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Nakashima, Ichiro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4F4X42SYQ6 |
|---|
| Anmerkungen: |
Date Completed 18.05.2023 Date Revised 18.05.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.11477/mf.1416202364 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356971066 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356971066 | ||
| 003 | DE-627 | ||
| 005 | 20231226071602.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||jpn c | ||
| 024 | 7 | |a 10.11477/mf.1416202364 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1189.xml |
| 035 | |a (DE-627)NLM356971066 | ||
| 035 | |a (NLM)37194518 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Nakashima, Ichiro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Therapeutic Strategies for Neuromyelitis Optica |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.05.2023 | ||
| 500 | |a Date Revised 18.05.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Treatments for acute attacks of neuromyelitis optica (NMO) include steroid pulse therapy, plasma exchange, and intravenous immunoglobulin. Oral immunosuppressants, such as prednisolone and azathioprine, have also been used to prevent relapse. Recently, biologic agents such as eculizumab, satralizumab, inebilizumab, and rituximab have been approved for use in Japan. Although side effects caused by steroid therapy have been issues for patients in the past, active use of the newly approved biologics is expected to help patients avoid the adverse effects of steroids and improve their qualities of life | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Azathioprine |2 NLM | |
| 650 | 7 | |a MRK240IY2L |2 NLM | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 650 | 7 | |a Aquaporin 4 |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Brain and nerve = Shinkei kenkyu no shinpo |d 2007 |g 75(2023), 5 vom: 17. Mai, Seite 493-497 |w (DE-627)NLM168920336 |x 1881-6096 |7 nnns |
| 773 | 1 | 8 | |g volume:75 |g year:2023 |g number:5 |g day:17 |g month:05 |g pages:493-497 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.11477/mf.1416202364 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 75 |j 2023 |e 5 |b 17 |c 05 |h 493-497 | ||